Original articleEffect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma☆
References (22)
- et al.
Thromboxane A2: effects on airway and vascular smooth muscle
Prostaglandins
(1977) - et al.
Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets
Eur J Pharmacol
(1983) - et al.
Effects of aerosol administration of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to acetylcholine in asthmatic subjects
Chest
(1990) - et al.
Attenuating effect of a thromboxane synthetase inhibitor (OKY-046) on bronchial responsiveness to methacholine is specific to bronchial asthma
Chest
(1990) - et al.
A novel anti-asthmatic quinone derivative, AA-2414, with a potent antagonistic activity against a variety of spasmogenic prostanoids
Prostaglandins
(1989) - et al.
Possible involvement of thromboxane in bronchoconstrictive and hypertensive effects of LTC4 and LTD4 in guinea pigs
Prostaglandins
(1982) - et al.
Bronchial hyperreactivity
Am Rev Respir Dis
(1980) - et al.
Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects
Thorax
(1986) - et al.
Standard for allergen bronchial provocation tests in asthma and hypersensitivity pneumonitis
Jpn J Allergol
(1982) - et al.
Involvement of thromboxane A2 in SRS-A mediated bronchoconstriction induced by aerosol antigen in the guinea pig
Kokyu
(1984)
Secondary release of thromboxane A2 in aerosol leukotriene C4-induced bronchoconstriction in guinea pigs
Prostaglandins
(1988)
Cited by (84)
Prostanoids
2009, Asthma and COPDProstanoids
2008, Asthma and COPD: Basic Mechanisms and Clinical ManagementNovel and emerging therapies for asthma
2005, Drug Discovery TodayCitation Excerpt :Early human studies demonstrated that seratrodast decreased PtdCho20 methacholine [the dose of methacholine that leads to a 20% drop in the forced expiratory volume (FEV)1] significantly after four days of oral administration. However, there was no change in baseline FEV1 and only 15 subjects were studied [10]. Theories on mechanism include a reduction of the number of activated eosinophils infiltrating the airways and releasing proinflammatory cytokines [11,12].
Possibility of non-steroidal treatment in allergic conjunctival diseases
2004, Allergology InternationalAdditive effect of cysteinyl leukotriene or thromboxane modifiers to inhaled corticosteroids in asthmatic patients
2004, Allergology International
- ☆
Supported in part by Ministry of Education, Science, and Culture Grant 01770510 of Japan.
Copyright © 1991 Published by Mosby, Inc.